Thymomas and thymic carcinomas are rare epithelial cell tumours arising from the thymus. Definitive surgical resection continues to be the primary approach for the management of thymomas and thymic carcinomas. However, complete resection is not always achievable due to the complexity of the mediastinal anatomy and in rare cases local recurrences may occur which are often incurable. Therefore, the use of Post-Operative Radiotherapy (PORT) may be considered with the intent of improving local control while being judicious of toxicity in the setting of prolonged clinical trajectories and proximity to critical structures. There continues to be a paucity of literature surrounding the use of PORT for thymomas and thymic carcinomas and the optimal dose has not yet been established. This review aims to summarize the current literature regarding radiotherapy indications and to explore issues surrounding radiotherapy dose-response-relationships for thymomas and thymic carcinoma. Long-term prospective studies using contemporary surgical and radiotherapy techniques are needed to further elucidate the optimal radiation approach in the management of thymic tumours.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794463 | PMC |
http://dx.doi.org/10.21037/med-20-4 | DOI Listing |
Cancers (Basel)
January 2025
Radiotherapy and Radiosurgery Department, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089 Milan, Italy.
Background: Radiotherapy for thymoma is delivered post-operatively in selected cases. Given the particular location of the thymic bed and the excellent prognosis, late cardiac toxicities may be an issue. The purpose of this retrospective dosimetric study is to investigate whether intensity-modulated proton beam therapy (IMPT) compared to photon therapy could better spare cardiac substructures, given prespecified dose constraints.
View Article and Find Full Text PDFCancer Rep (Hoboken)
January 2025
Department of Thoracic Surgery, Affiliated Hospital of Zunyi Medical College, Zunyi, People's Republic of China.
Background: Neuroendocrine tumors of the thymus (NETT) are rare and malignant tumors that arise in the anterior mediastinum. These tumors can exhibit aggressive behavior and may involve surrounding critical structures, such as the superior vena cava. This case contributes to the literature by presenting a recurrent thymic carcinoma with invasion of major blood vessels, including the superior vena cava, and the complexities involved in its surgical management.
View Article and Find Full Text PDFInt J Surg Case Rep
January 2025
Maharajgunj Medical Campus, Institute of Medicine, Tribhuvan University Teaching Hospital, Nepal.
Introduction And Importance: Thymoma is the most common primary anterior mediastinal tumor in adults. Invasive thymomas infiltrate organs adjacent to the mediastinal pleura, including the lungs, great vessels, heart, pericardium, and diaphragm. Complete resection of invasive thymoma leads to a better prognosis.
View Article and Find Full Text PDFGland Surg
December 2024
Department of Thoracic Surgery and Oncology, State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Background: Thymomas and thymic carcinomas are rare and aggressive thymic tumors that are usually detected in advanced stages. Surgery is the mainstay of treatment; however, the role of surgery in advanced disease is controversial due to factors such as myasthenia gravis; thus, decisions about whether to perform surgical interventions are complex. Further studies need to be conducted to explore the potential benefits of surgery in the treatment of advanced thymic tumors.
View Article and Find Full Text PDFActa Oncol
January 2025
Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark.
Background And Purpose: We report the incidence, characteristics, and comorbidities of the complete unselected Danish cohort of patients with thymic epitheliums (TETs), which may serve as evidence for guiding treatment, surveillance, and counselling of TET patients.
Patients And Methods: All patients diagnosed with TETs from January 1st, 2015, to December 31st, 2020, were identified using the Danish Pathology Data Registry. Data on patient characteristics, comorbidities, and tumor histology were collected from electronic medical records available for all patients.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!